Anti-CD33 Monoclonal Antibody M195 for the Therapy of Myeloid Leukemia

References

• Foon K. A., Gale R. P. Therapy of acute my-elogenous leukemia. Blood Rev. 1992; 6: 15–25
   PubMed Web of Science ®Google Scholar
• Scheinberg D. A. Monoclonal antibodies in the treatment of myelogenous leukemias. Leukemia: Advances Research and Treatment, E. J. Freireich, H. Km-Tarjian. Kluwer Academic Publishers, Boston 1993; 213–232
   Google Scholar
• Grossbard M. L., Press O. W., Appelbaum F. R., Bemstein I. D., Nadler L. M. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992; 80: 863–878
   PubMed Web of Science ®Google Scholar
• Tanimoto M., Scheinberg D. A., Cordon-Cardo C., Huie D., Clarkson B. D., Old L. J. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia (Baltimore) 1989; 3: 339–348
   PubMed Web of Science ®Google Scholar
• Scheinberg D. A., Tanimoto M., McKenzie S., Strife A., Old L. J., Clarkson B. D. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia (Baltimore) 1989; 3: 440–445
   PubMed Web of Science ®Google Scholar
• Lemoli R. M., Gasparetto C., Scheinberg D. A., Moore M. A. S., Clarkson B. D., Gulati S. C. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. Blood 1991; 77: 1829–1836
   PubMed Web of Science ®Google Scholar
• Scheinberg D. A., Lovett D., Divgi C. R., Graham M. C., Berman E., Pentlow K., Feirt N., Finn R. D., Clarkson B. D., Gee T. S., Larson S. M., Oettgen H. F., Old L. J. A Phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J. Clin. Oncol. 1991; 9: 478–490
   PubMed Web of Science ®Google Scholar
• Schwartz M. A., Lovett D. R., Redner A., Finn R. D., Graham M. C., Divgi C. R., Dantis L., Gee T. S., An-Dreeff M., Old L. J., Larson S. M., Scheinberg D. A. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J. Clin. Oncol. 1993; 11: 294–303
   PubMed Web of Science ®Google Scholar
• Co M. S., Avdalovic N. M., Caron P. C., Avdalovic M. V., Scheinberg D. A., Queen C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J. Immunol. 1992; 148: 1149–1154
   PubMed Web of Science ®Google Scholar
• Hale G., Clark M. R., Marcus R., Winter G., Dyer M. J. S., Phillips J. M., Riechmann L., Waldmann H. Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2: 1394–1399
   PubMed Web of Science ®Google Scholar
• Junghans R. P., Waldrnann T. A., Landolfi N. F., Avddlovic N. M., Schneider W. P., Queen C. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 1990; 50: 1495–1502
   PubMed Web of Science ®Google Scholar
• Co M. S., Deschamps M., Whitley R. J., Queen C. Humanized antibodies for antiviral therapy. Proc. Natl. Acad. Sci. (USA) 1991; 88: 2869–2874
   PubMed Web of Science ®Google Scholar
• Singer I. I., Kawka D. W., DeMartino J. A., Daugherty B. L., Elliston K. O., Alves K., Bush B. L., Cameron P. M., Cuca G. C., Davies P., Forrest M. J., Kazazis D. M., Law M.F., Lenny A. B., MacIntyre D. E., Meurer R., Padlan E. A., Pandya S., Schmidt J. A., Seamans T. C., Scott S., Silberklang M., Williamson A. R., Mark G. E. Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences. J. Immunol. 1993; 150: 2844–2857
   PubMed Web of Science ®Google Scholar
• Caron P. C., Co Man Sung, Bull M. K., Avdalovic N. M., Queen C., Scheinberg D. A. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res. 1992; 52: 6761–6767
   PubMed Web of Science ®Google Scholar
• Caron P. C., Scott A., Graham M., Divgi C. R., Jurcic J. G., Finn R., Sgouros G., Dantis L., Old L. J., Larson S. M., Scheinberg D. A. Specific targeting of humanized anti-CD33 monoclonal antibody M195: a phase I trail for acute rnyelogenous leukemia. Proc. Am. Assoc. Clin. Oncol. 1993; 12: 311
   Google Scholar
• LoBuglio A. F., Wheeler R. H., Trang J., Haynes A., Rogers K., Harvey E. B., Ghrayeb J., Khazaeli M. B. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. (USA) 1989; 86: 4220–4224
   PubMed Web of Science ®Google Scholar
• Jurcic J. G., Caron P. C., Miller W. H., Maslak P., Weiss M., Gulati S., Finn R., Larson S. M., Warrell R. P., Scheinberg D. A. Prospects for elimination of minimal residual disease in APL using 131I-M195 (anti-CD33) after remission induction with all-trans-retinoic acid. Proc. Am. Assoc. Clin. Oncol. 1993; 12: 311
   Google Scholar
• Warrell R. P., Frankel S. R., Miller W. H., Scheinberg D. A., Itri L. M., Hittelman W. N., Vyas R., Andreeff M., Tafuri A., Jakubowski A., Gabrilove J., Gordon M. S., Dmitrovsky E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. 1991; 324: 1385–1393
   PubMed Web of Science ®Google Scholar
• Fenaux P. Management of acute promyelocytic leukemia. Eur. J. Haematol. 1993; 50: 65–73
   PubMed Web of Science ®Google Scholar
• Miller W. H., Kakizuka A., Frankel S. R., Warrell R. P., DeBlasio A., Levine K., Evans R. M., Dmitrovsky E. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc. Natl. Acad. Sci. (USA) 1992; 89: 2694–2698
   PubMed Web of Science ®Google Scholar
• Appelbaum F. R., Matthews D. C., Eary J. F., Badger C. C., Kellogg M., Press O. W., Martin P. J., Fisher D. R., Nelp W. B., Thomas E. D., Bernstein I. D. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992; 54: 829–833
   PubMed Web of Science ®Google Scholar
• Brown P. S., Parenteau G. L., Dirbas F. M., Garsia R. J., Goldman C. K., Bukowski M. A., Junghans R. P., Queen C., Hakim J., Benjamin W. R., Clark R. E., Waldmann T. A. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allo-graft survival. Proc. Natl. Acad. Sci. (USA) 1991; 88: 2663–2667
   PubMed Web of Science ®Google Scholar
• Calgiuri M. A., Murray C., Soiffer R. J., Klumpp T. R., Seiden M., Cochran K., Cameron C., Ish C., Buchanan L., Perillo D., Smith K., Ritz J. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J. Clin. Oncol. 1991; 9: 2110–2119
   PubMed Web of Science ®Google Scholar
• Smith K. Lowest dose interleukin-2 therapy. Blood 1993; 81: 1414–1423
   PubMed Web of Science ®Google Scholar
• Caron P. C., Laird W., Co Man Sung, Avdalovic N. M., Queen C., Scheinberg D. A. Engineered humanized dimeric forms of IgG are more effective antibodies. J. Exp. Med. 1992; 176: 1191–1195
   PubMed Web of Science ®Google Scholar